You will notice that a huge amount of what is on clinicaltrials.gov has zero data also, it's not just Burzynski.
All you need to know about Burzynski and Antineoplastons is one thing. He has been given permission by the USA Food & Drug Adminstration for Phase 3 randomized trials for diffuse intrinisc brainstem glioma.
No medicine or medical center has ever, ever, cured this tumor type before. Burzynski has a 27.5% cure rate with this tumor. A first in medical history. Antineoplastons are also the first in medical history to make it to Phase 3 trials for this tumor type.
Here is an email from the FDA to Burzynski proving this: https://www.burzynskimovie.com/images/stories/Understanding/EmailFromFDA_Phase3_ANP.pdf
Also, these Phase 2 clinical trials have been published in the peer-reviewed literature. Why people keep saying he hasn't been published, is like the people saying Obama isn't a citizen or climate change isn't real, or the earth is flat.
Link to example peer-reviewed article on brainstem glioma (see page 172 for a mind blowing account of the results compared to traditional therapy):
http://www.burzynskiclinic.com/images/Pub_SRB_2006_Treatment_for_Astrocytic_Tumors_in_Children_Ped%20Drugs.pdf
Reading Wiki to find honest info will not work. Read the actual data. You will notice that Wiki and all the blogs cherry pick and take things out of context to make sure the public doesn't realize the reality of this therapy. No different than the electric car or any past innovations that have been marginalized.
You will notice that when you present that data I just posted, people will become numb, eyes will gloss over, and they will retreat into denial. Good luck with your journey, I hope you are able to decipher reality from fiction.
Recent BZYR News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/29/2024 08:15:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 09:15:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/12/2023 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/13/2023 08:15:24 PM
FEATURED Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM